Abodakpi Henrietta, Wanger Audrey, Tam Vincent H
Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy, Houston, TX, USA.
Department of Pathology and Laboratory Medicine, McGovern Medical School, 6431 Fannin, Houston, Texas 77030, USA.
Clin Lab Med. 2019 Sep;39(3):473-485. doi: 10.1016/j.cll.2019.05.006. Epub 2019 Jul 6.
As a class, β-lactamase inhibitors have proved successful in extending the clinical utility of β-lactam antibiotics by circumventing β-lactamase-mediated resistance. However, the rapid evolution of these β-lactamases calls for a critical reevaluation of the relationships between susceptibility, drug exposures, and bacterial response. The existing paradigm for in vitro susceptibility testing and development of β-lactam/β-lactamase inhibitor combinations may not optimally facilitate clinical use. Thus, alternative approaches for pairing these combinations and evaluating in vitro susceptibility are needed to provide better guidance to clinicians.
作为一类药物，β-内酰胺酶抑制剂已被证明可通过克服β-内酰胺酶介导的耐药性来成功扩展β-内酰胺类抗生素的临床应用。然而，这些β-内酰胺酶的快速进化要求对敏感性、药物暴露和细菌反应之间的关系进行严格的重新评估。现有的体外药敏试验和β-内酰胺/β-内酰胺酶抑制剂联合用药研发模式可能无法最佳地促进临床应用。因此，需要采用其他方法来组合这些联合用药并评估体外药敏性，以便为临床医生提供更好的指导。
